📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
5 articles
AVG GRADE
NEUTRAL
score: 0.40
SENTIMENT
NEUTRAL
TOTAL VIEWS
56
KYMR Latest News & AI Sentiment Analysis
5 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 11 ARTICLES
Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KYMR) 2026-08-05
Kymera Therapeutics (KYMR) released its 2026 Q2 earnings presentation, providing operational and financial updates to investors. The...
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics (KYMR) reported Q2 2026 earnings via earnings call transcript released on August 5, 2026. While the full transcript...
Kymera Therapeutics Q2 Earnings Call Highlights
KYMR announced accelerated enrollment completion in its Phase 2b atopic dermatitis trial for KT-621, finishing approximately six months...
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics (KYMR) reported Q2 2026 results with a material clinical catalyst: completion of enrollment in the KT-621 BROADEN2...
Kymera Therapeutics Q2 2026 Earnings Preview (NASDAQ:KYMR)
Kymera Therapeutics (KYMR) is scheduled to release second-quarter 2026 financial results on August 5 in the premarket session. This is a...
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Kymera Therapeutics announced the appointment of Dr. Terence Rooney as Chief Medical Officer, bringing immunology expertise from Johnson...
Kymera's CEO Sold $6 Million in Stock After a 170% Run
KYMR experienced a routine executive equity liquidation within a pre-scheduled Rule 10b5-1 trading plan, following extraordinary stock...
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade) (NASDAQ:KYMR)
Kymera Therapeutics (KYMR) received an upgrade to Buy, reflecting analyst confidence in the company's clinical development trajectory...
Kymera: Building Toward A Defining 2H26 Moment (NASDAQ:KYMR)
Kymera Therapeutics (KYMR) has received a Buy rating from analyst commentary centered on anticipated clinical trial catalysts in the...
Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?
TECH (Bio-Techne) leads biotech gainers following acquisition announcement, representing a material capital event for the company and...
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics announced a board leadership transition with Felix J. Baker, Ph.D., assuming the role of Chairman, while co-founder...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice